Online inquiry

IVTScrip™ mRNA-Anti-CD274, MSB-0010718C(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ12280MR)

This product GTTS-WQ12280MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets CD274 gene. The antibody can be applied in Renal Cell Carcinoma (RCC), Merkel cell carcinoma (MCC) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001267706.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 29126
UniProt ID Q9NZQ7
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD274, MSB-0010718C(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ12280MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ4628MR IVTScrip™ mRNA-Anti-LAG3, BMS-986016(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BMS-986016
GTTS-WQ5165MR IVTScrip™ mRNA-Anti-Canlupfam IL31, CAN34D3-65(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA CAN34D3-65
GTTS-WQ14603MR IVTScrip™ mRNA-Anti-DLL3, SC0001(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA SC0001
GTTS-WQ10663MR IVTScrip™ mRNA-Anti-S, LY-3819253(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA LY-3819253
GTTS-WQ2940MR IVTScrip™ mRNA-Anti-PDCD1, ANB-011(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ANB-011
GTTS-WQ6120MR IVTScrip™ mRNA-Anti-IL6, COR-001(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA COR-001
GTTS-WQ8698MR IVTScrip™ mRNA-Anti-F3, HuMax-TF(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA HuMax-TF
GTTS-WQ11166MR IVTScrip™ mRNA-Anti-IFNAR1, MDX-1333(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA MDX-1333
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW